Cancer News

Immunotherapy Active Against Triple-Negative Breast Cancer (10/12/2017)

October is breast cancer awareness month and patients with triple-negative breast cancer (TNBC) should be aware that data from two clinical trials provide additional evidence that they may derive benefit from checkpoint inhibitor therapy.1-4 About Triple Negative Breast Cancer Approximately 12% of breast cancers are triple-negative breast cancers, meaning that they are estrogen-receptor negative (ER-), …

Continue reading "Immunotherapy Active Against Triple-Negative Breast Cancer"

LynparzaTM Slows Spread of Inherited Breast Cancer Caused By BRCA Mutations (10/10/2017)

LynparzaTM (olaparib), a new drug treatment for women with advanced ovarian cancer associated with defective BRCA genes also appears to slowe the progression of breast cancer caused in part by mutations in the BRCA gene.  BRCA is an inherited condition that causes up to 3% of all breast cancers. BRCA + breast cancer is particularly …

Continue reading "LynparzaTM Slows Spread of Inherited Breast Cancer Caused By BRCA Mutations"

FDA approves new treatment for certain advanced or metastatic breast cancers (10/05/2017)

The U.S. Food and Drug Administration today approved Verzenio (abemaciclib) to treat adult patients who have hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer that has progressed after taking therapy that alters a patient’s hormones (endocrine therapy). Verzenio is approved to be given in combination with an endocrine …

Continue reading "FDA approves new treatment for certain advanced or metastatic breast cancers"

Annual Mammography Starting at Age 40 Prevents the Most Cancer Deaths (09/13/2017)

When to initiate screening for breast cancer, how often to screen, and how long to screen are questions that continue to spark emotional debates. A new study compares the number of deaths that might be prevented as a result of three of the most widely discussed recommendations for screening mammography. Published early online in Cancer, …

Continue reading "Annual Mammography Starting at Age 40 Prevents the Most Cancer Deaths"

FDA Grants Breakthrough Therapy Designation to DS-8201 for HER2-Positive Metastatic Breast Cancer (08/30/2017)

The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to DS-8201, an investigational HER2-targeting antibody drug conjugate (ADC), for the treatment of patients with HER2-positive, locally advanced or metastatic breast cancer who have been treated with Herceptin and Perjeta and have disease progression after ado-trastuzumab (T-DM1). Breakthrough Therapy designation is designed to …

Continue reading "FDA Grants Breakthrough Therapy Designation to DS-8201 for HER2-Positive Metastatic Breast Cancer"

Nipple-Sparing Mastectomy Has Low Rate of Breast Cancer Recurrence (08/01/2017)

Investigators say most women with breast cancer are eligible for this type of mastectomy, which leaves the natural nipple in place Women with breast cancer who undergo nipple-sparing mastectomy (NSM) have a low rate of the cancer returning within the first five years, when most recurrences in the breast are diagnosed, findings of a single-center …

Continue reading "Nipple-Sparing Mastectomy Has Low Rate of Breast Cancer Recurrence"

Balance and Gait is Negatively Impacted By Chemotherapy Treatment (07/26/2017)

A single chemotherapy treatment can result in a significant negative impact on walking gait and balance, putting patients at an increasing risk for falls, according to a new study involving breast cancer patients conducted by researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research …

Continue reading "Balance and Gait is Negatively Impacted By Chemotherapy Treatment"

FDA Approves Nerlynx for Treatment of Early Stage HER2-Positive Breast Cancer (07/18/2017)

The U.S. Food and Drug Administration approved Nerlynx (eratinib) for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, to follow adjuvant trastuzumab-based therapy. Approval was based on the ExteNET trial (NCT00878709), a multicenter, randomized, double-blind, placebo-controlled trial of Nerlynx following adjuvant trastuzumab treatment. Women (n=2,840) with early-stage HER2-positive breast cancer …

Continue reading "FDA Approves Nerlynx for Treatment of Early Stage HER2-Positive Breast Cancer"

Immunotherapy with Checkpoint Inhibitor Durvalumab Show Promise in Triple Negative Breast Cancer (06/22/2017)

Doctors from Yale Cancer Center presented new data at the American Society of Clinical Oncology meeting on the impact of combining the immune checkpoint inhibitor (durvalumab/MEDI4736) with chemotherapy as preoperative treatment for early stage triple negative breast cancer (TNBC).  Overall patients with TNBC achieved a 71% pathologic complete response to the combination treatment in the …

Continue reading "Immunotherapy with Checkpoint Inhibitor Durvalumab Show Promise in Triple Negative Breast Cancer"

Shows Improved Outcomes with Addition of Keytruda® in Triple Negative High-Risk Breast Cancer (06/09/2017)

The results from the I-SPY 2 TRIAL investigating Keyytruda (pembrolizumab), in combination with standard therapy as a pre-operative (neoadjuvant) treatment for patients with locally advanced breast cancer were released at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.  The estimated pathologic complete response (pCR) rate increased nearly threefold in patients with triple-negative …

Continue reading "Shows Improved Outcomes with Addition of Keytruda® in Triple Negative High-Risk Breast Cancer"